Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged strategy to address neurological health, focusing on its investigational multiple sclerosis therapy Lucid-MS and its proprietary dietary supplement unbuzzd. This dual approach underscores the company's commitment to tackling challenging neurodegenerative and metabolic disorders, as well as alcohol misuse, through innovative science and commercial products.
The core of the strategy lies in Lucid-MS, a patented new chemical entity designed to target PAD2, an enzyme associated with myelin degradation. Unlike conventional MS therapies that primarily modulate the immune system, Lucid-MS aims to protect and potentially restore the myelin sheath, offering a disease-modifying approach that could alter the progression of multiple sclerosis. The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 trial, and is supporting the development through an imaging collaboration with Massachusetts General Hospital. This partnership is expected to provide critical insights into the drug's effect on myelin integrity, potentially accelerating its path to clinical validation.
In parallel, Quantum BioPharma's unbuzzd supplement is designed to support alcohol metabolism, reduce acute intoxication, and mitigate hangover effects. The company cites results from a randomized, placebo-controlled clinical trial that demonstrated its efficacy. Notably, Quantum BioPharma has spun out the over-the-counter version of unbuzzd to Unbuzzd Wellness Inc. (UWI), led by industry veterans, while retaining a 19.84% ownership stake as of March 31, 2026. The agreement also includes royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop pharmaceutical and medical formulations of similar products, positioning it to capitalize on both the consumer and medical markets.
The strategic importance of this dual approach cannot be overstated. For Lucid-MS, the potential to reverse myelin degradation represents a paradigm shift in MS treatment, moving beyond symptom management to potentially halting or reversing disability progression. If successful, it could address a significant unmet medical need for the estimated 2.8 million people worldwide living with MS. The FDA's acceptance of the IND application is a critical milestone, and the collaboration with Massachusetts General Hospital adds scientific rigor to the development process, enhancing the credibility of the program.
On the unbuzzd front, the product taps into a growing consumer demand for wellness solutions that mitigate the effects of alcohol. The clinical trial results provide a scientific foundation that could differentiate unbuzzd in a crowded market. The royalty structure and retained rights ensure that Quantum BioPharma benefits from unbuzzd's commercial success while preserving the ability to develop prescription-grade versions for medical use, such as treatments for alcohol use disorder. This diversification reduces risk and creates multiple revenue streams.
Quantum BioPharma's commitment to building a portfolio of innovative assets is evident in its pipeline and strategic partnerships. The company's focus on both therapeutic and consumer health products positions it uniquely in the biotech landscape. As it advances Lucid-MS through clinical trials and commercializes unbuzzd, the company aims to deliver meaningful improvements in neurological health.
The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
